11 / 35
Infectious Diseases 2018
Journal of Prevention and Infection Control
ISSN: 2471-9668
Page 49
June 07-08, 2018
London, UK
8
th
Edition of International Conference on
Infectious Diseases
T
o develop recombinase polymerase amplification assays for
detection of
Coxiella burnetii
, this is the causative agent of
highly fatal Q fever. Because the clinical symptom of Q fever is
not typical, the disease can be easily missed and misdiagnosed.
Sensitive, specific and rapid diagnostic tests for the detection
of
Coxiella burnetii
are necessary to accurately and promptly
diagnose patients and ensure that they receive proper treatment.
Recombinase polymerase amplification (RPA) assays using a
lateral flow test (RPA-nfo) were developed targeting the 23SrRNA
geneof
Coxiellaburnetii
.Agroupof specificprimersandprobeswith
high amplification efficiency at 37°C was screened successfully,
and the concentration of reverse primer and the probe was 5 μM,
respectively. Furthermore, the RPA-nfo reaction was completed in
20 minutes at 37°C followed by 3-5 minutes incubation at room
temperature for development of an immunochromatographic strip.
All the results showed that the constructed RPA detection system
has good specificity for detection of
Coxiella burnetii
without
cross-reaction with other viruses, and can detect
Coxiella burnetii
at levels comparable to that of the quantitative PCR method. The
constructed RPA detection system showed superior detection
performance, which could provide technical support for
Coxiella
burnetii
in site detection.
Biography
Li Yuexi has his expertise in development of diagnostic reagent and vac-
cine of infectious diseases. He has developed more than 100 diagnostic
reagents and got 87 licenses from CFDA, including ELISA, gold-labeled im-
munochromatographic strip, qPCR, LAMP, RPA, and DNA chip. He is also
developing several infectious diseases vaccines, such as herpes simplex
virus, mycoplasma pneumoniae, etc.
liyxi2007@126.comDevelopment of recombinase polymerase amplification assays
for detection of Coxiella burnetii
Li Yuexi
1, 2, 3
, Qi Yong
1
, Yin Qiong
1, 2
, Shao Yinxiu
1, 2
, Li jiameng
1
, Rao Jixian
1
, Li Xiaol-
ing
1, 2
, Zheng Shulong
1, 2
, Lin Yu
1, 2
and
Deng Yi
1, 2
1
Huadong Research Institute for Medicine and Biotechniques, China
2
China Pharmaceutical University, China
3
Nanjing Medical University, China
Li Yuexi et al., J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-9668-C1-003